These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35414081)

  • 1. Assessment of glycemia in chronic kidney disease.
    Hassanein M; Shafi T
    BMC Med; 2022 Apr; 20(1):117. PubMed ID: 35414081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease.
    Zelnick LR; Batacchi ZO; Ahmad I; Dighe A; Little RR; Trence DL; Hirsch IB; de Boer IH
    Diabetes Care; 2020 Oct; 43(10):2379-2387. PubMed ID: 32788282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality.
    Copur S; Onal EM; Afsar B; Ortiz A; van Raalte DH; Cherney DZ; Rossing P; Kanbay M
    J Diabetes Complications; 2020 Nov; 34(11):107707. PubMed ID: 32861562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Glycemic control in patients with diabetes mellitus on hemodialysis].
    Lobanova KG; Severina AS; Martinov SA; Shamkhalova MS; Shestakova MV
    Ter Arkh; 2019 Oct; 91(10):124-134. PubMed ID: 32598642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does CKD affect HbA1c?
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2018 Apr; 10(4):270. PubMed ID: 29124865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment.
    Konya J; Ng JM; Cox H; Cooke M; Lewis N; Bhandari S; Atkin SL; Kilpatrick ES
    Diabet Med; 2013 Oct; 30(10):1250-4. PubMed ID: 23758176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications and pitfalls of hemoglobin A1C and alternative methods of glycemic monitoring.
    Lundholm MD; Emanuele MA; Ashraf A; Nadeem S
    J Diabetes Complications; 2020 Aug; 34(8):107585. PubMed ID: 32553575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic Kidney Disease: Is There a Role for Glycemic Variability?
    Subramanian S; Hirsch IB
    Curr Diab Rep; 2018 Feb; 18(3):13. PubMed ID: 29450720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis.
    Gallieni M; De Salvo C; Lunati ME; Rossi A; D'Addio F; Pastore I; Sabiu G; Miglio R; Zuccotti GV; Fiorina P
    Acta Diabetol; 2021 Aug; 58(8):975-981. PubMed ID: 33743082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemoglobin A
    Chan CL; Hope E; Thurston J; Vigers T; Pyle L; Zeitler PS; Nadeau KJ
    Diabetes Care; 2018 Jul; 41(7):1406-1413. PubMed ID: 29674323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous Glucose Monitoring to Optimize Management of Diabetes in Patients with Advanced CKD.
    Galindo RJ; de Boer IH; Neumiller JJ; Tuttle KR
    Clin J Am Soc Nephrol; 2023 Jan; 18(1):130-145. PubMed ID: 36719162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.
    Chan CL; Pyle L; Kelsey MM; Newnes L; Baumgartner A; Zeitler PS; Nadeau KJ
    Pediatr Diabetes; 2017 Nov; 18(7):629-636. PubMed ID: 27873436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary protein glycosylation as a noninvasive biomarker for assessment of glycemia.
    Rao PV; Laurie A; Bean ES; Roberts CT; Nagalla SR
    J Diabetes Sci Technol; 2015 Jan; 9(1):97-104. PubMed ID: 25305283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Study Comparing Glycated Albumin to Other Glycemic Indices.
    Desouza CV; Holcomb RG; Rosenstock J; Frias JP; Hsia SH; Klein EJ; Zhou R; Kohzuma T; Fonseca VA
    J Clin Endocrinol Metab; 2020 Mar; 105(3):677-87. PubMed ID: 31650161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose.
    Juraschek SP; Steffes MW; Selvin E
    Clin Chem; 2012 Dec; 58(12):1648-55. PubMed ID: 23019309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?
    Speeckaert M; Van Biesen W; Delanghe J; Slingerland R; Wiecek A; Heaf J; Drechsler C; Lacatus R; Vanholder R; Nistor I;
    Nephrol Dial Transplant; 2014 Dec; 29(12):2167-77. PubMed ID: 24470517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond self-monitored plasma glucose and HbA1c: the role of non-traditional glycaemic markers in gestational diabetes mellitus.
    Mendes N; Tavares Ribeiro R; Serrano F
    J Obstet Gynaecol; 2018 Aug; 38(6):762-769. PubMed ID: 29620435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of home glucose monitoring with determinations of hemoglobin A1c, total glycated hemoglobin, fructosamine, and random serum glucose in diabetic patients.
    Gebhart SS; Wheaton RN; Mullins RE; Austin GE
    Arch Intern Med; 1991 Jun; 151(6):1133-7. PubMed ID: 2043015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical discrepancy in blood glucose control levels evaluated by glycated albumin and estimated hemoglobin A1c levels determined from a flash continuous glucose monitoring system in patients with type 2 diabetes on hemodialysis.
    Ushigome E; Matsusaki S; Watanabe N; Hashimoto T; Nakamura N; Fukui M
    J Diabetes Investig; 2020 Nov; 11(6):1570-1574. PubMed ID: 32356596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma 1,5-anhydroglucitol concentration in patients with end-stage renal disease with and without diabetes mellitus.
    Emoto M; Tabata T; Inoue T; Nishizawa Y; Morii H
    Nephron; 1992; 61(2):181-6. PubMed ID: 1630543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.